Jonathan Palmer

Glenn, there's so many things I want to ask about in that response.

I have a couple of follow-ups on Accolade, but I think I'll push those aside for a little while because I think wayfinding is a great segue here.

So I believe you started that in 2024.

Can you talk about the evolution of the technology and the platform and ending with today with your press release around some of the new capabilities?

And I'd love to know that $100 million, where is it going?

Is it going to engineers?

Is it going to...

I don't know.

Tell me.

Where do you think this goes from an acuity perspective?

I mean, I think a sprained ankle or a sinus infection is kind of a low acuity event.

Do you have to put on guardrails to maybe slow it down and get that human interaction?

You used the suicide prevention case before, but if I think of somebody who's got cancer or is maybe having some sort of medication problem,

Is this going to be able to tackle those sorts of cases today or in the future?

No, it's fascinating.

You know, staying on this vein of technology, I'd love to get your insight on where you think, or maybe said better, what are you excited about over the next, and I don't know what the right timeframe is here, because everything's moving so quickly, whether it's 12 months, three years.

When you look outside, TransKaren, about what's changing in the world of healthcare, you know, as we're putting more AI and models into the system, what are you most excited about?

Maybe to segue back to Accolade for a little while, you've closed the acquisition less than a year in, I believe.

What has pleasantly surprised you about the organization?

And I imagine there must have been one or two things that maybe didn't work out as well.